Moderna, Inc. (MRNA) — SEC Financial Statements & Analysis

Moderna, Inc. (MRNA) is a biological products, (no diagnostic substances) company, incorporated in DE. Moderna, Inc. trades on Nasdaq as: MRNA. Moderna, Inc. (MRNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31. Based on that filing, Moderna, Inc. carries a market cap of $27.87B, a P/E ratio of -8.85x, a P/B ratio of 4.12x, a P/S ratio of 12.51x, an enterprise value of $26.74B, and an EV/EBITDA multiple of -8.05x. On profitability, it posts a gross margin of 23.38%, an operating margin of -149.01%, a net margin of -141.43%, a Return on Equity (ROE) of -39.00%, a Return on Assets (ROA) of -27.43%, and a Return on Invested Capital (ROIC) of -47.82%. Per share, it reports EPS of $-7.92, diluted EPS of $-7.92, free cash flow per share of $-3.13, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -27.62% year-over-year, net income growth of 8.54% year-over-year, and EPS growth of 5.82% year-over-year. On the balance sheet, it maintains a current ratio of 2.29x, a quick ratio of 2.03x, working capital of $3.28B, a debt-to-equity ratio of 0.62x, a debt ratio of 0.38, free cash flow of $-1.24B (TTM), and net debt of $-1.13B. Figures sourced from SEC EDGAR.

Market Cap

$27.87B

P/E TTM

-8.85x

EPS TTM

$-7.92

P/B TTM

4.12x

ROE TTM

-39.00%

ROA TTM

-27.43%

Debt To Equity

0.62x

Free Cash Flow TTM

$-1.24B

Net Revenue TTM Growth 1Y

-27.62%

Data as of 2026-06-30 · Source: SEC EDGAR